Elevated Pulmonary Artery Systolic Pressure is Associated with Poor Survival of Patients with Non-Small Cell Lung Cancer

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2020 Aug 22

PMID 32821155

Citations 6

Authors

Xue Yang

Lina Wang

Lianjun Lin

Xinmin Liu

Affiliations

Soon will be listed here.

Abstract

Purpose: Pulmonary hypertension (PH) is an important comorbidity of lung cancer, PH in lung cancer patients is gradually gaining interest because of its apparent high prevalence, but the impact of PH on the outcomes of lung cancer remains uncertain and had rarely been discussed. We aimed to evaluate the prevalence, determinants and prognosis value of elevated pulmonary artery systolic pressure (PASP) in non-small cell lung cancer patients.

Patients And Methods: In this retrospective study, subjects with a new and pathological confirmed diagnosis of lung cancer were enrolled. All patients underwent transthoracic echocardiography before received treatment. Pulmonary artery systolic pressure was measured by transthoracic echocardiography. Lung cancer subtypes were categorized by WHO classification of lung tumors. Hazard ratios (HR) were estimated by using Cox regression models.

Results: Among 612 non-small cell lung cancer (NSCLC) patients, 19.8% coexisted with PH. After adjustment for age, symptom, coagulation disorders, lymph node metastasis, distant metastasis, histological type, clinical stage, PASP ≥35mmHg was significantly associated with the decreased overall survival (OS) of NSCLC (P= 0.028). Moreover, PASP ≥45mmHg was an independent predictor for perioperative death. Independent factors of comorbid elevated PASP were age, the presence of intrapulmonary metastasis and coagulation disorders.

Conclusion: These findings suggest that PASP is an independent prognostic risk factor for NSCLC patients. Main determinants of elevated PASP are age, the presence of intrapulmonary metastasis and coagulation disorders.

Citing Articles

Non-cancerous CT findings as predictors of survival outcome in advanced non-small cell lung cancer patients treated with first-generation EGFR-TKIs.

Prakaikietikul P, Tajarenmuang P, Losuriya P, Ina N, Ketpueak T, Kanthawang T PLoS One. 2025; 20(2):e0313577.

PMID: 39908320 PMC: 11798445. DOI: 10.1371/journal.pone.0313577.

Pulmonary Hypertension and Survival among Non-Small Cell Lung Cancer Patients: A Retrospective Cohort Study in the U.S. Military Health System.

Nations J, Lin J, Park A, Shriver C, Zhu K J Clin Med. 2024; 13(11).

PMID: 38892928 PMC: 11173320. DOI: 10.3390/jcm13113217.

Relative Loss of Small Pulmonary Vessels on Imaging and Risk of Recurrence of Resected Lung Adenocarcinoma.

Synn A, Litchman T, de Margerie-Mellon C, Bankier A, Rahaghi F, Washko G Ann Am Thorac Soc. 2023; 20(11):1673-1676.

PMID: 37590317 PMC: 10632925. DOI: 10.1513/AnnalsATS.202303-191RL.

Impact of pulmonary arterial systolic pressure on patients with mitral valve disease combined with atrial fibrillation.

Zheng T, Zhao Y, Ye Q, Zheng S, Meng F, Hu Q Front Cardiovasc Med. 2023; 9:1047715.

PMID: 36698961 PMC: 9868267. DOI: 10.3389/fcvm.2022.1047715.

Death without progression as an endpoint to describe cardiac radiation effects in locally advanced non-small cell lung cancer.

Yegya-Raman N, Kegelman T, Lee S, Kallan M, Kim K, Natarajan J Clin Transl Radiat Oncol. 2023; 39:100581.

PMID: 36691564 PMC: 9860414. DOI: 10.1016/j.ctro.2023.100581.

References

Culley M, Chan S . Mitochondrial metabolism in pulmonary hypertension: beyond mountains there are mountains. J Clin Invest. 2018; 128(9):3704-3715. PMC: 6118596. DOI: 10.1172/JCI120847. View

Lam C, Borlaug B, Kane G, Enders F, Rodeheffer R, Redfield M . Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation. 2009; 119(20):2663-70. PMC: 2753443. DOI: 10.1161/CIRCULATIONAHA.108.838698. View

Pullamsetti S, Kojonazarov B, Storn S, Gall H, Salazar Y, Wolf J . Lung cancer-associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell-immune cell cross-talk. Sci Transl Med. 2017; 9(416). DOI: 10.1126/scitranslmed.aai9048. View

Sugimura H, Yang P . Long-term survivorship in lung cancer: a review. Chest. 2006; 129(4):1088-97. DOI: 10.1378/chest.129.4.1088. View

Bravos E, Cottin V, Dauphin C, Bouvaist H, Traclet J, Tresorier R . Cancer incidence in patients with pre-capillary pulmonary hypertension. J Heart Lung Transplant. 2019; 38(7):778-780. DOI: 10.1016/j.healun.2019.03.007. View

Galie N, McLaughlin V, Rubin L, Simonneau G . An overview of the 6th World Symposium on Pulmonary Hypertension. Eur Respir J. 2018; 53(1). PMC: 6351332. DOI: 10.1183/13993003.02148-2018. View

Simonneau G, Montani D, Celermajer D, Denton C, Gatzoulis M, Krowka M . Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2018; 53(1). PMC: 6351336. DOI: 10.1183/13993003.01913-2018. View

Geschwind J, Dagli M, Vogel-Claussen J, Seifter E, Huncharek M . Metastatic breast carcinoma presenting as a large pulmonary embolus: case report and review of the literature. Am J Clin Oncol. 2003; 26(1):89-91. DOI: 10.1097/00000421-200302000-00017. View

Kramer M, Estenne M, Berkman N, Antoine M, de Francquen P, Lipski A . Radiation-induced pulmonary veno-occlusive disease. Chest. 1993; 104(4):1282-4. DOI: 10.1378/chest.104.4.1282. View

10.

Barta J, Powell C, Wisnivesky J . Global Epidemiology of Lung Cancer. Ann Glob Health. 2019; 85(1). PMC: 6724220. DOI: 10.5334/aogh.2419. View

11.

Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M . Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391(10125):1023-1075. PMC: 5879496. DOI: 10.1016/S0140-6736(17)33326-3. View

12.

Quintanal-Villalonga A, Molina-Pinelo S . Epigenetics of lung cancer: a translational perspective. Cell Oncol (Dordr). 2019; 42(6):739-756. DOI: 10.1007/s13402-019-00465-9. View

13.

Rudski L, Lai W, Afilalo J, Hua L, Handschumacher M, Chandrasekaran K . Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology,.... J Am Soc Echocardiogr. 2010; 23(7):685-713. DOI: 10.1016/j.echo.2010.05.010. View

14.

Yock P, Popp R . Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation. 1984; 70(4):657-62. DOI: 10.1161/01.cir.70.4.657. View

15.

Chemla D, Humbert M, Sitbon O, Montani D, Herve P . Systolic and mean pulmonary artery pressures: are they interchangeable in patients with pulmonary hypertension?. Chest. 2015; 147(4):943-950. DOI: 10.1378/chest.14-1755. View

16.

Uruga H, Fujii T, Kurosaki A, Hanada S, Takaya H, Miyamoto A . Pulmonary tumor thrombotic microangiopathy: a clinical analysis of 30 autopsy cases. Intern Med. 2013; 52(12):1317-23. DOI: 10.2169/internalmedicine.52.9472. View

17.

Thenappan T, Ormiston M, Ryan J, Archer S . Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018; 360:j5492. PMC: 6889979. DOI: 10.1136/bmj.j5492. View

18.

Kumar N, Price L, Angeles Montero M, Dimopoulos K, Wells A, Wort S . Pulmonary tumour thrombotic microangiopathy: unclassifiable pulmonary hypertension?. Eur Respir J. 2015; 46(4):1214-7. DOI: 10.1183/13993003.00052-2015. View

19.

Roberts K, Hamele-Bena D, Saqi A, Stein C, Cole R . Pulmonary tumor embolism: a review of the literature. Am J Med. 2003; 115(3):228-32. DOI: 10.1016/s0002-9343(03)00305-x. View

20.

McGee M, Whitehead N, Martin J, Collins N . Drug-associated pulmonary arterial hypertension. Clin Toxicol (Phila). 2018; 56(9):801-809. DOI: 10.1080/15563650.2018.1447119. View